{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:41:40Z","timestamp":1764996100682,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T00:00:00Z","timestamp":1476748800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0720-2","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T09:35:45Z","timestamp":1476783345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Severe inflammatory disease activity 14\u00a0months after cessation of Natalizumab in a patient with Leber\u2019s optic neuropathy and multiple sclerosis \u2013 a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-5664","authenticated-orcid":false,"given":"Trygve","family":"Holm\u00f8y","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonie G.","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetozar","family":"Zarnovicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aija Zuleron","family":"Myro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egil","family":"R\u00f8sj\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Kerty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,18]]},"reference":[{"key":"720_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/08820538.2015.1115251","volume":"31","author":"N Rasool","year":"2016","unstructured":"Rasool N, Lessell S, Cestari DM. Leber hereditary optic neuropathy: bringing the lab to the clinic. Semin Ophthalmol. 2016;31:107\u201316.","journal-title":"Semin Ophthalmol"},{"key":"720_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jns.2009.09.009","volume":"286","author":"J Palace","year":"2009","unstructured":"Palace J. Multiple sclerosis associated with Leber's hereditary optic neuropathy. J Neurol Sci. 2009;286:24\u20137.","journal-title":"J Neurol Sci"},{"issue":"Pt 4","key":"720_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/brain\/115.4.979","volume":"115","author":"AE Harding","year":"1992","unstructured":"Harding AE, Sweeney MG, Miller DH, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain. 1992;115(Pt 4):979\u201389.","journal-title":"Brain"},{"key":"720_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/jnnp-2014-308186","volume":"86","author":"L Matthews","year":"2015","unstructured":"Matthews L, Enzinger C, Fazekas F, et al. MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:537\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","volume":"16","author":"M Rasenack","year":"2016","unstructured":"Rasenack M, Derfuss T. Disease activity return after natalizumab cessation in multiple sclerosis. Expert Rev Neurother. 2016;16:587\u201394.","journal-title":"Expert Rev Neurother"},{"key":"720_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O'Connor","year":"2011","unstructured":"O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858\u201365.","journal-title":"Neurology"},{"key":"720_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","volume":"71","author":"M Clerico","year":"2014","unstructured":"Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol. 2014;71:954\u201360.","journal-title":"JAMA Neurol"},{"key":"720_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","volume":"261","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261:1170\u20137.","journal-title":"J Neurol"},{"key":"720_CR9","doi-asserted-by":"publisher","unstructured":"Larochelle C, Metz I, Lecuyer MA, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler. 2016. doi:\n                    10.1177\/1352458516641775\n                    \n                  . [Epub ahead of print].","DOI":"10.1177\/1352458516641775"},{"key":"720_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1352458514549401","volume":"21","author":"A Vidal-Jordana","year":"2015","unstructured":"Vidal-Jordana A, Tintore M, Tur C, et al. Significant clinical worsening after natalizumab withdrawal: Predictive factors. Mult Scler. 2015;21:780\u20135.","journal-title":"Mult Scler"},{"key":"720_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","volume":"8","author":"J Borchardt","year":"2016","unstructured":"Borchardt J, Berger JR. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord. 2016;8:145\u201350.","journal-title":"Mult Scler Relat Disord"},{"key":"720_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archneurol.2010.257","volume":"68","author":"A Miravalle","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68:186\u201391.","journal-title":"Arch Neurol"},{"key":"720_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"BO Khatri","year":"2009","unstructured":"Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:402\u20139.","journal-title":"Neurology"},{"key":"720_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/1352458511431073","volume":"18","author":"T Rispens","year":"2012","unstructured":"Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler. 2012;18:899\u2013901.","journal-title":"Mult Scler"},{"key":"720_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1553","volume":"27","author":"AF Labrijn","year":"2009","unstructured":"Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767\u201371.","journal-title":"Nat Biotechnol"},{"key":"720_CR16","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1212\/01.wnl.0000437308.22603.43","volume":"81","author":"G Pfeffer","year":"2013","unstructured":"Pfeffer G, Burke A, Yu-Wai-Man P, Compston DA, Chinnery PF. Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations. Neurology. 2013;81:2073\u201381.","journal-title":"Neurology"},{"key":"720_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s004150050015","volume":"247","author":"R Horvath","year":"2000","unstructured":"Horvath R, Abicht A, Shoubridge EA, et al. Leber's hereditary optic neuropathy presenting as multiple sclerosis-like disease of the CNS. J Neurol. 2000;247:65\u20137.","journal-title":"J Neurol"},{"key":"720_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/brain\/awh310","volume":"128","author":"GG Kovacs","year":"2005","unstructured":"Kovacs GG, Hoftberger R, Majtenyi K, et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain. 2005;128:35\u201341.","journal-title":"Brain"},{"key":"720_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","volume":"333","author":"H Lassmann","year":"2013","unstructured":"Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013;333:1\u20134.","journal-title":"J Neurol Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-016-0720-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T15:44:36Z","timestamp":1487691876000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,18]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0720-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2016,10,18]]},"article-number":"197"}}